---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-25-000007"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2025-02-04T23:59:59+00:00"
generated_at: "2026-05-27T03:47:58.993759+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q4 revenue up 10% to $3.79B; initiates $0.88 quarterly dividend, adds $3B buyback

## Summary
- Q4 GAAP diluted EPS $8.06 (-21% YoY); non-GAAP diluted EPS $12.07 (+2% YoY). Full year revenue $14.20B (+8%).
- Q4 Dupixent global net sales $3.70B (+15%); EYLEA HD/EYLEA US net sales $1.50B (+2%); Libtayo global $367M (+50%).
- Initiated quarterly cash dividend of $0.88/share, payable March 20, 2025. Board authorized additional $3.0B share repurchase (total capacity ~$4.5B).
- Regulatory applications submitted for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid, linvoseltamab, and odronextamab.

## SEC filing metadata
- accession: 0001804220-25-000007
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2025-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/0001804220-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/regn-20250204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-25-000007
- JSON: https://secwatch.observer/filing/0001804220-25-000007.json
- Plain text: https://secwatch.observer/filing/0001804220-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.